Liver Angiosarcoma Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Liver Angiosarcoma Epidemiology Forecast Report Coverage

Expert Market Research's “Liver Angiosarcoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of liver angiosarcoma. It projects the future incidence and prevalence rates of liver angiosarcoma cases across various populations. The study covers age, gender, and type as major determinants of the liver angiosarcoma population. The report highlights patterns in the prevalence of liver angiosarcoma over time and projects future trends based on multiple variables.

Liver Angiosarcoma Understanding: Disease Overview

Liver angiosarcoma is a rare, aggressive vascular malignancy originating from hepatic endothelial cells. It accounts for less than 2% of primary liver cancers and is often linked to exposure to vinyl chloride, arsenic, or thorium dioxide. The disease predominantly affects older adults and presents with nonspecific symptoms such as abdominal pain, hepatomegaly, and jaundice. Diagnosis is challenging due to rapid progression and late detection. Prognosis remains poor, with median survival typically less than six months post-diagnosis.

Liver Angiosarcoma Epidemiology Perspective

The liver angiosarcoma epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the liver angiosarcoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for liver angiosarcoma and their trends. The liver angiosarcoma detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Tumor arises from malignant transformation of hepatic sinusoidal or vascular endothelial cells. Associated with chromosomal abnormalities, such as mutations in TP53, K-ras, and activation of angiogenic pathways (VEGF, FGF).
• Liver cancer is the 6th most common cancer globally, and is one of the rarest liver cancers, representing only 0.1%-2% of all primary hepatic malignancies worldwide.
• The estimated incidence for liver angiosarcoma is 0.5-2.5 cases per 10 million people (≈ 0.05-0.25 per 100 000).
• Liver angiosarcoma predominantly affects individuals aged over 60 years, highlighting its strong association with aging and cumulative environmental exposures.
• The disease exhibits a marked male predominance, with approximately 64% of cases occurring in men and a male-to-female ratio of about 3:1.

Read more about this report - Request a Free Sample

Country-wise Liver Angiosarcoma Epidemiology Segment

The liver angiosarcoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, liver angiosarcoma remains an exceptionally rare hepatic malignancy, accounting for less than 1% of primary liver cancers. Recent epidemiological findings estimate an annual incidence of approximately 0.14 to 0.25 cases per million people, reflecting its rarity across the nation. The disease typically presents in older adults, with a strong male predominance and poor clinical outcomes due to its aggressive nature. Continued advancements in diagnostic awareness and early detection strategies are essential to improving management and outcomes for this uncommon but severe liver cancer.

Liver Angiosarcoma: Treatment Overview

The treatment options for liver angiosarcoma are limited due to its diffuse and multifocal presentation. Surgical resection offers potential benefit only in localized disease, though recurrence is common. Transarterial chemoembolization (TACE) and systemic chemotherapy with agents such as doxorubicin or paclitaxel may provide temporary control. Liver transplantation is generally contraindicated due to high recurrence risk. Emerging strategies exploring targeted anti-angiogenic therapies and immunotherapy are under investigation but remain experimental. Supportive care remains essential to improve quality of life.

Key Questions Answered

• What are the key findings of liver angiosarcoma epidemiology in the 8 major markets?
• What will be the total number of patients with liver angiosarcoma across the 8 major markets during the forecast period?
• What was the country-wise liver angiosarcoma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of liver angiosarcoma during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of liver angiosarcoma during the forecast period of 2026-2035?
• What are the currently available treatments for liver angiosarcoma?
• What are the disease risks, signs, symptoms, and unmet needs of liver angiosarcoma?

Scope of the Liver Angiosarcoma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of liver angiosarcoma based on several factors.
• Liver Angiosarcoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The liver angiosarcoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Liver Cirrhosis Pipeline Analysis

Liver Disease Treatment Market